Public Notes

UPSC foundations · Note 220

Patents and intellectual property in science

Science · Reference edition 1 November 2026 · 2 min read

Study context: GS III — Science and Technology — developments and their applications and effects in everyday life; achievements of Indians in science & technology; indigenisation of technology and developing new technology.

A patent gives an inventor a time-limited exclusive right to an invention, in exchange for disclosing how it works. The bargain is meant to reward innovation while eventually letting others build on it. India's Patents Act dates to 1970, and a major amendment in 2005 introduced product patents for pharmaceuticals and other fields, bringing India into compliance with the World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights, known as TRIPS.

The 2005 change was controversial because product patents can raise medicine prices by delaying generic competition. Indian law therefore kept safeguards: Section 3(d) refuses patents for mere new forms of known substances unless they show enhanced efficacy, and the law allows compulsory licensing, where the government permits production of a patented product without the patent holder's consent in defined public-interest circumstances. The Supreme Court's 2013 decision in the Novartis case, rejecting a patent claim under Section 3(d), became the leading example of how these safeguards work in practice.

Intellectual property extends beyond patents. Copyright protects creative works, trademarks protect brands, geographical indications protect products linked to a place, such as Darjeeling tea or Banarasi silk, and plant variety protection covers new crop varieties. The National Intellectual Property Rights Policy of 2016 aimed to make this system work as a whole, raising awareness, improving administration and using intellectual property to support innovation and creativity rather than treating it as a legal formality.

Administration matters as much as law. Patent examination backlogs, the quality of granted patents, and the cost of enforcement decide whether small firms and universities can actually use the system. A patent that takes many years to grant may be worthless for a fast-moving technology, and a weak patent that should never have been granted can block competitors unfairly. Digitisation and examiner capacity are therefore practical, not bureaucratic, issues.

For civil studies, intellectual property is a balance question. Too little protection discourages investment in research; too much protection, or protection for trivial changes, raises prices and blocks follow-on innovation. The Indian system's distinctive feature is its deliberate attempt to hold that balance through safeguards, and examination answers should show both sides of the bargain.

Key takeaways

  • The Patents Act of 1970 was amended in 2005 to introduce product patents under TRIPS.
  • Section 3(d) and compulsory licensing are safeguards for access, tested in the 2013 Novartis decision.
  • The National Intellectual Property Rights Policy dates to 2016.

Why it matters for civil studies

Intellectual property links innovation incentives, access to medicines and trade obligations.

Think it through

When a patent raises the price of a life-saving drug, whose interest should prevail: the inventor's, or the patient's?

From the Public Notes companion study collection. Editorial context and corrections.

WhatsApp